List of Excipients in API belzutifan
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing belzutifan
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | WELIREG | belzutifan | 0006-5331 | CELLULOSE, MICROCRYSTALLINE | 2034-09-05 |
| Merck Sharp & Dohme LLC | WELIREG | belzutifan | 0006-5331 | CROSCARMELLOSE SODIUM | 2034-09-05 |
| Merck Sharp & Dohme LLC | WELIREG | belzutifan | 0006-5331 | FD&C BLUE NO. 2 ALUMINUM LAKE | 2034-09-05 |
| Merck Sharp & Dohme LLC | WELIREG | belzutifan | 0006-5331 | HYPROMELLOSE ACETATE SUCCINATE 06081224 | 2034-09-05 |
| Merck Sharp & Dohme LLC | WELIREG | belzutifan | 0006-5331 | MAGNESIUM STEARATE | 2034-09-05 |
| Merck Sharp & Dohme LLC | WELIREG | belzutifan | 0006-5331 | MANNITOL | 2034-09-05 |
| Merck Sharp & Dohme LLC | WELIREG | belzutifan | 0006-5331 | POLYETHYLENE GLYCOL | 2034-09-05 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for belzutifan
Excipient focus: CELLULOSE, MICROCRYSTALLINE
belzutifan drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
belzutifan drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 2 ALUMINUM LAKE
belzutifan drug variants containing FD&C BLUE NO. 2 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing FD&C BLUE NO. 2 ALUMINUM LAKE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: HYPROMELLOSE ACETATE SUCCINATE 06081224
belzutifan drug variants containing HYPROMELLOSE ACETATE SUCCINATE 06081224
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing HYPROMELLOSE ACETATE SUCCINATE 06081224
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
belzutifan drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MANNITOL
belzutifan drug variants containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing MANNITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL
belzutifan drug variants containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing POLYETHYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
belzutifan drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SILICON DIOXIDE
belzutifan drug variants containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing SILICON DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
belzutifan drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
belzutifan drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Merck Sharp & Dohme LLC | belzutifan | 0006-5331 |
| >Company | >Ingredient | >NDC |
belzutifan drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
